Commissioning and dosimetric verification of volumetric modulated arc therapy for multiple modalities using electronic portal imaging device-based 3D dosimetry system: a novel approach.

The purpose of this study was to validate an electronic portal imaging device (EPID) based 3-dimensional (3D) dosimetry system for the commissioning of volumetric modulated arc therapy (VMAT) delivery for flattening filter (FF) and flattening filter free (FFF) modalities based on test suites developed according to American Association of Physicists in Medicine Task Group 119 (AAPM TG 119) and pre-treatment patient specific quality assurance (PSQA).With ionisation chamber, multiple-point measurement in various planes becomes extremely difficult and time-consuming, necessitating repeated exposure of the plan. The average agreement between measured and planned doses for TG plans is recommended to be within 3%, and both the ionisation chamber and PerFRACTION™ measurement were well within this prescribed limit. Both point dose differences with the planned dose and gamma passing rates are comparable with TG reported multi-institution results. From our study, we found that no significant differences were found between FF and FFF beams for measurements using PerFRACTION™ and ion chamber. Overall, PerFRACTION™ produces acceptable results to be used for commissioning and validating VMAT and for performing PSQA. The findings support the feasibility of integrating PerFRACTION™ into routine quality assurance procedures for VMAT delivery. Further multi-institutional studies are recommended to establish global baseline values and enhance the understanding of PerFRACTION™'s capabilities in diverse clinical settings.

Quality assurance of lead aprons for radiation protection.

Radiation protection is essential to minimize the harmful effects of ionizing radiation. Lead equivalent apron is one of the common protective devices to reduce the occupational risk of radiation exposure. The aim of the study is to analyse the percentage attenuation of 0.5 mm lead equivalent apron. Twenty aprons were used for calculating the percentage of attenuation. The computed tomography (CT) phantom was placed on the radiography and CT table at 1 m from the X-ray tube. The readings were taken from the phantom using a detector at 1-m distance with and without lead equivalent aprons. The readings were tabulated and analysed. The mean percentage attenuation of 0.5 mm lead equivalent apron is 95.66 ± 0.61 in radiography (100 kVp), 95.64 ± 0.57 in CT (130 kVp), respectively. The percentage attenuation of lead equivalent aprons is permissible comparing with the literature.

Analysis of fetal dose using Optically Simulated Luminescence Dosimeter and ion chamber in randophantom for various radiotherapy techniques.

To analyse the fetal dose in all three trimesters in patients treated for brain tumors during pregnancy, a modified rando phantom representing three different trimesters was used with provisions for insertion of ion-chamber and Optically Simulated Luminescence Dosimeter (OSLD). The measurement regions were chosen at the level of fundus, umbilicus and pubis. Seven different treatment plans with 6FF and 6FFF beam energies were generated. Treating pregnant patients with brain tumors is safe irrespective of planning modalities except 3DCRT plan where the dose is 10.24 cGy.

Dose Estimation Using Optically Stimulated Luminescence Dosimeter and EBT3 Films for Various Treatment Techniques in Alderson Rando Phantom and Estimation of Secondary Cancer Incidence for Carcinoma of Left Breast.

Aim: The aim of this study was to measure the dose to planning target and organ at risk (OAR) using Alderson Rando phantom for various treatment techniques in left breast radiotherapy and to estimate the secondary cancer incidence. Materials and Methods: Eleven different combinations of plans containing four techniques (three dimensional conformal radiotherapy, intensity-modulated radiation therapy [IMRT], volumetric modulated arc therapy [VMAT], and combination of 3DCRT and VMAT plans (HYBRID)) were created with 6 MV FF and 6 MV FFF (flattening filter and flattening filter-free) photon energies in phantom. Planned target volume and OAR doses in 23 different locations were measured using optically stimulated luminescence dosimeter (OSLD) and EBT3 films. Assuming the age of exposure as 30 years, lifetime attributable risk (LAR) was estimated based on excess absolute risk (EAR) models outlined in the Biological Effects of Ionizing Radiation VII report. Results: Film showed maximum deviations of 6.15% with IMRT_C_FF plan when compared with treatment planning system (TPS). The maximum percentage difference of 1.7% was found with OSLD measurement when compared with TPS for VMAT_T_FFF plan. EAR estimation was done for all the OARs including target. The LARs for left lung, right lung, and right breast were evaluated. The maximum LAR values of 2.92 ± 0.14 were found for left lung with VMAT_C_FFF plans. Conclusion: This study shows that both OSLD and EBT3 films are suitable for dose measurements using Rando phantom. OSLD shows superior results when compared with films, especially with relatively larger distances. Maximum LAR values were found with VMAT_C_FFF plans. Considering the secondary cancer risk associated with the patients treated in the younger age group, it is suggested that in vivo dose estimation should be a part of treatment quality audit whenever possible.

Verification of Surface Dose for Flattening Filter and Flattening Filter Free Beams in Beam-Matched Medical Linear Accelerators.

BACKGROUND: The purpose of this study was to evaluate the surface dose (SD) of 6 and 10 MV flattening filter beam (FF) and flattening filter free (FFF) beam for different square field sizes in three Beam-matched medical linear accelerators using a parallel-plate ionization chamber. MATERIALS AND METHODS: The experiment was carried out in a phantom composed of 40×40 cm2 solid Water slabs of varying thickness. Further sheets of solid water phantom were added to take readings in the build-up region for both SSD and SAD technique. Surface doses are measured with a PPC-05 chamber and DOSE 1 electrometer, at measurement depth of 1 mm interval and all results are plotted relative to the dose measured at Dmax for various field sizes. Surface dose readings are therefore reported as relative surface dose. RESULTS: Surface dose increased linearly with field size for both FF and FFF photon beams in all three beam-matched linear accelerators in both SSD and SAD setup. The surface dose of FFF was higher than FF beams in all field sizes. For the given energy the surface dose difference (relative to 10x10 cm2 field size of 6FF) between FF and FFF beam was larger for large field size. For 6FF and 6FFF beam the surface dose difference for 5x5 cm2 is -5.27%, and for 30x30 cm2 it is 12.91%. The measured surface dose differences between linear accelerators are not statically significant (P>0.989). Similarly, the surface dose difference between SSD and SAD setup was also analysed and had no statistical significance (P>0.849). CONCLUSION: Study showed that the surface dose difference between beam-matched linear accelerators are insignificant. The surface dose difference between SSD and SAD setup were also found negligible. Most importantly, changing patients between beam-matched linear accelerators will not have any significant changes in surface dose in clinical setup.
.

Targeting Notch signalling pathway of cancer stem cells.

Cancer stem cells (CSCs) have been defined as cells within tumor that possess the capacity to self-renew and to cause the heterogeneous lineages of cancer cells that comprise the tumor. CSCs have been increasingly identified in blood cancer, prostate, ovarian, lung, melanoma, pancreatic, colon, brain and many more malignancies. CSCs have slow growth rate and are resistant to chemotherapy and radiotherapy that lead to the failure of traditional current therapy. Eradicating the CSCs and recurrence, is promising aspect for the cure of cancer. The CSCs like any other stem cells activate the signal transduction pathways that involve the development and tissue homeostasis, which include Notch signaling pathway. The new treatment targets these pathway that control stem-cell replication, survival and differentiation that are under development. Notch inhibitors either single or in combination with chemotherapy drugs have been developed to treat cancer and its recurrence. This approach of targeting signaling pathway of CSCs represents a promising future direction for the therapeutic strategy to cure cancer.